Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

ible for the development

of the Staccato Electric Multiple Dose device, and the Company has the

exclusive right to manufacture the product for clinical development

and commercial supply.

-- AZ-007 (Staccato zaleplon). Alexza is developing AZ-007 for the

treatment of insomnia in patients who have difficulty falling asleep,

including patients who awake in the middle of the night and have

difficulty falling back asleep. In March 2008, Alexza completed

enrollment in a Phase 1 clinical trial of 40 healthy volunteers at a

single U.S. clinical center. The purpose of this trial was to assess

the safety, tolerability and pharmacokinetic parameters of a single

dose of AZ-007. Using a double-blind, randomized, dose-escalation

trial design, 4 doses of AZ-007 (ranging from 0.5 to 4.0 mg) were

compared to placebo.

In April 2008, Alexza announced positive initial results from the Phase 1 study. AZ-007 delivered an IV-like pharmacokinetic profile with a median time to peak venous concentration (Tmax) of 1.6 minutes. Zaleplon exposure was dose proportional across the 4 doses studied, as calculated by power analysis. Pharmacodynamics, measured as sedation self-assessed on a 100 mm visual-analog scale, showed onset of effect as early as 2 minutes after dosing with AZ-007. There were no serious adverse events. The most frequently reported adverse events in subjects receiving AZ-007 were dizziness and somnolence. These data indicate a rapid onset of effect, apparently directly related to the IV-like pharmacokinetics, and showed that AZ-007 was generally safe and well tolerated in this population of healthy volunteers.

Conference Call Information

Alexza will host a conference call today at 4:30 p.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to al
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The synthetic rubber ... get such derivatives as ethylbenzene, a precursor to styrene, used to make styrene-butadiene ... industry for the production of tyres and other components. Thus, growth in the ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... pumps to its comprehensive line of analytical laboratory equipment. With optimized features, such ... pumps provide a chemically resistant and maintenance-free solution for a broad range of ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... In its third year as a contestent, Vector Surgical ... to improve breast cancer surgery, is the winner of the ... the winner in the life sciences category, beat out three ... the Wisconsin Entrepreneurs' Conference . The 2007 contest, produced ...
... Matt Storms is writing a series of articles on raising ... on managing the offering process after the Private Placement Memorandum ... , ,Here's a conversation overheard at a recent conference: , ... investors since showing up two hours ago. Each of ...
... member of Congress announces that a major reason to reform the ... does it like us. , ,Even during an era when America-bashing ... well - and has always done well - much to the ... things is innovation. In fact, the United States is the greatest ...
Cached Biology Technology:Surgical products company wins Governor's Business Plan Contest 2Surgical products company wins Governor's Business Plan Contest 3Surgical products company wins Governor's Business Plan Contest 4In pursuit of capital, be sure to track your private offering 2In pursuit of capital, be sure to track your private offering 3In pursuit of capital, be sure to track your private offering 4In pursuit of capital, be sure to track your private offering 5In pursuit of capital, be sure to track your private offering 6Changes to U.S. patent law must nurture our culture of innovation 2Changes to U.S. patent law must nurture our culture of innovation 3Changes to U.S. patent law must nurture our culture of innovation 4
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... chromosomes, which are normally bar-shaped, instead bend into a ... cause a multitude of problems. Genetics experts at The ... disorder, supported by a $126,000 grant from the Ring ... because it affects the 20th of the 23 human ...
... National Human Genome Research Institute (NHGRI), part of the ... more than $80 million over the next four years ... which in its pilot phase yielded provocative new insights ... Based on ENCODEs early success, we are moving ...
... Springer, one of the leading global STM publishers, has ... (ERF) for the journal Estuaries and Coasts. Appearing ... role in promoting research on and management of estuarine ... Springer will be February 2008. The partnership will ...
Cached Biology News:Grant supports study of abnormal ring-shaped chromosomes 2Researchers expand efforts to explore functional landscape of the human genome 2Researchers expand efforts to explore functional landscape of the human genome 3Researchers expand efforts to explore functional landscape of the human genome 4Researchers expand efforts to explore functional landscape of the human genome 5Researchers expand efforts to explore functional landscape of the human genome 6Estuarine Research Federation chooses Springer as publishing partner 2
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
VAP-1 (S-13)...
... contains 4 deuterium atoms at the 3, ... intended for use as an internal standard ... by GC- or LC-mass spectrometry. PGE2 is ... arachidonic acid and one of the most ...
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Biology Products: